MMprofiler publications

Scientific Background References for the MMprofiler

1. Chng, W.J. e.a. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106, 2156-2161 (2005). Link

2. Moreaux, J. e.a. CD200 is a new prognostic factor in multiple myeloma. Blood 108, 4194-4197 (2006). Link

3. Fonseca, R. e.a. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk. Lymphoma 35, 599-605 (1999). Link

4. Bergsagel, P.L. e.a. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296-303 (2005). Link

5. Cremer, F.W. e.a. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44, 194-203 (2005). Link

6. Smadja, N.V. e.a. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38, 234-239 (2003). Link

7. Broyl, A. e.a. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543-2553 (2010). Link

8. Smadja, N.V., Bastard, C., Brigaudeau, C., Leroux, D. & Fruchart, C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98, 2229-2238 (2001). Link

9. Keats, J.J. e.a. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101, 1520-1529 (2003). Link

10. Agnelli, L. e.a. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 92, 56-65 (2007). Link

11. Chng, W.J. e.a. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 67, 2982-2989 (2007). Link

12. Bergsagel, P.L. & Kuehl, W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol 23, 6333-6338 (2005). Link

13. Kyle, R.A. & Rajkumar, S.V. Multiple myeloma. N. Engl. J. Med 351, 1860-1873 (2004). Link

14. Decaux, O. e.a. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J. Clin. Oncol 26, 4798-4805 (2008). Link

15. Zhan, F. e.a. The molecular classification of multiple myeloma. Blood 108, 2020-2028 (2006). Link

16. Fonseca, R. e.a. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102, 2562-2567 (2003). Link

17. Blood. 2012 Jan 23. IMWG consensus on maintenance therapy in multiple myeloma. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. Link

18. Eur J Cancer. 2011 Jul;47(10):1458-67. Epub 2011 May 9. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Gaultney JG, Redekop WK, Sonneveld P, Uyl-de Groot CA. Link

19. Int J Hematol. 2011 Oct;94(4):321-33. Epub 2011 Oct 15. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr. Link